Liver cancer combo trial halted early: what happened?

NCT ID NCT05199285

Terminated Disease control Sponsor: Academic and Community Cancer Research United Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times

Summary

This study tested whether combining two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors in people with advanced liver cancer that had already spread or couldn't be removed by surgery. All 15 participants had previously tried another immunotherapy combination (atezolizumab + bevacizumab) without success. The trial was terminated early, so results are limited, but the goal was to see if this new combo could offer another treatment option for hard-to-treat liver cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
University of Alabama- Birmingham

Birmingham, Alabama, 35233, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136, United States
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.